Core Viewpoint - The law firm Wohl & Fruchter LLP is investigating the fairness of the proposed sale of STAAR Surgical Company to Alcon, Inc. for $28.00 per share, which is significantly lower than STAAR's 52-week high of $41.00 per share, indicating a potentially opportunistic acquisition by Alcon [1][3]. Group 1 - The sale price of $28.00 per share is well below STAAR's 52-week high of $41.00, raising concerns about the fairness of the transaction [1][3]. - Investor sentiment is negative, with at least two investors expressing disappointment over the sale price on SeekingAlpha, citing the future potential of STAAR's implantable lenses for vision correction [2][3]. - Wohl & Fruchter LLP is investigating whether the STAAR Board of Directors acted in the best interests of shareholders and if all material information regarding the transaction was disclosed [4]. Group 2 - One investor criticized the urgency of the sale, suggesting that STAAR's future potential is worth significantly more than the proposed sale price, estimating it to be around ten billion [4]. - Another investor remarked that if the sale goes through, Alcon would have secured an exceptionally favorable deal [4].